The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Introduction
============

Replenishing the regular health decays is the vital requirement of human health that is satisfied through sleep cycles. Sleep is a mandatory part of life that naturally rejuvenates us physiologically, biochemically, and at the cellular and molecular level as well. On average, more than 30% of human life is spent sleeping \[[@REF1]\]. Apart from rejuvenation, sleep is directly associated with the proper function of the central nervous system, blood pressure maintenance, metabolism, catabolism, temperature regulation, memory consolidation and several other essential physiological functions \[[@REF2]\]. In recent times, Insomnia or sleeplessness has become a common disorder that is affecting a large global population and impairing the general health and mental wellbeing. Insomnia is clinically characterized by difficulty in sleep onset or sleep maintenance or a combination of both and impairment of daily functionalities. The clinical criteria that designate insomnia are average sleep latency of more than 30 min, wakefulness after sleep onset of more than 30 min, sleep efficiency of less than 85% of total sleep time of fewer than 6.5 hours \[[@REF3]\]. Insomnia often leads to fatigue, energy depletion, impairment in concentration and increased irritability. Investigations of etiological and pathophysiological factors since decades suggest that the onset and the progress of insomnia depend on multiple factors including genetic, cognitive and behavioral, physiological, biochemical, and environmental \[[@REF4]\]. Impact of the cumulative effect of these factors often leads to other physiological and clinical complications such as autonomic nervous system (ANS) activation through altered heart rate, body temperature variation, varying metabolism, deviated function of the hormonal axis such as hypothalamic-pituitary-adrenal axis. The prognosis on onset and progress of insomnia is debatable and widely varies from case to case. Multiple factors can induce the disease condition including stress, anxiety, asthma, altering hormonal cycle, lifestyle modification and other disease conditions such as cancer \[[@REF3]\]. Association of insomnia with chronic diseases, such as obesity, type 2 diabetes, cardiovascular disease, neurological issues including mood swings, increased mortality has been established as evidenced by available literature \[[@REF5]\]. A survey suggests, more than 80% global population use plant extracts as medication for primary health care \[[@REF6],[@REF7]\]. Ashwagandha found across India and south Asia, is a respected herb in traditional Indian Ayurveda, scientifically known as Withania somnifera (L.) Dunal. It is a member of the Solanaceae family \[[@REF8]\]. The practitioners of Ayurveda regard Ashwagandha as a multipurpose and a valuable herb due to the extensive use of different plant parts to treat a variety of ailments. In Ayurveda, Ashwagandha has been utilized for centuries as a "Rasayana" and an adaptogen \[[@REF9]\].

Many studies have been conducted on the root extracts of Ashwagandha. In vitro studies on Ashwagandha root extracts have demonstrated its neuroprotective, anti-inflammatory and chondroprotective effects \[[@REF10],[@REF11]\]. Experiments using animal models indicated cardio-protective, immunomodulatory, anti-diabetic and neuroprotective effects of Ashwagandha root extracts \[[@REF12]-[@REF15]\]. Clinical studies conducted in various conditions suggest that Ashwagandha root extract improves sexual performances in both males and females, aids in reducing and managing stress and anxiety, improves memory and cognition in healthy adults and patients with bipolar disorder \[[@REF16]-[@REF20]\]. This multipurpose herb also increases muscle strength, muscle size and supports in muscle recovery \[[@REF21]\].

In the present study, we have investigated the impact of Ashwagandha root extract powder compared to placebo on insomnia patients as a natural solution to the burgeoning problem of insomnia. The sleep-wake cycle was monitored using actigraphy devices which were simple and effective apart from analysis of sleep logs. Scientific literature evidence suggests that the sleep parameters estimated sleep actigraphy are sleep onset latency (SOL), total sleep time (TST), sleep efficiency (SE) and wake after sleep onset (WASO) \[[@REF22]\]. Sleep actigraphy is a validated tool and has become a common practice along with standard sleep logs for sleep studies. A self-rated questionnaire, such as the Pittsburgh Sleep Quality Index (PSQI), was used to measure the quality and disturbances of sleep in adults. PSQI has seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications and daytime dysfunction over the last month \[[@REF23]\]. The Hamilton Anxiety Rating Scale (HAM-A) used in our study is another important first rating scale developed to measure the severity of anxiety symptoms. HAM-A consists of 14 elements and caters for both psychological and somatic symptoms \[[@REF24]\].

Materials and methods
=====================

Study objectives

Primary objective was to compare the effects of Ashwagandha root extract and placebo on the SOL assessed by actigraphy. The secondary objectives include comparing the effects of Ashwagandha root extract versus placebo i) on the total sleep time (TST), Wake After Sleep Onset (WASO) and Sleep Efficiency (SE) assessed by actigraphy; ii) on sleep quality using the Pittsburgh Sleep Quality Index (PSQI), mental alertness on rising and sleep quality using Sleep logs; iii) on anxiety score using the Hamilton-Anxiety (HAM-A) scale (Figure [1](#FIG1){ref-type="fig"}).
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Study design

This was a randomized, double-blind, placebo-controlled study conducted between November 2014 and March 2015. A total of 60 patients with insomnia were randomized in a 2:1 ratio to receive Ashwagandha root extract (KSM 66 capsule) or identical placebo for a period of 10 weeks. The study was conducted in accordance with the Helsinki Declaration (1989 amendment) and the study protocol was approved by an Institutional Ethics Committee (Reference number: ECR/66/Inst/MH/2013), Snehal Hospital, Thane dated 30 October 2014. Ethics Committee (EC) notifications were followed as per Good Clinical Practice (GCP) guidelines, issued by CDSCO and ethical guidelines for biomedical research on human patients, issued by Indian Council of Medical Research (ICMR). The Consolidated Standards Of Reporting Trials (CONSORT) guidelines for designing and reporting controlled trials were followed in this study. Written informed consent was obtained from all participants prior to the enrolment. Each patient was explained in detail about the study objective and the expected outcome before taking the consent.

Study participants

The study population included 60 participants aged between 18 and 60 years. Participants were selected from several outpatient clinics and invited to the study centre (Prakruti Hospital, Kalwa, Thane, Mumbai, India). Participants were informed about the study and were assessed by the principal investigator for eligibility based on the inclusion/exclusion criteria. Both male and female patients who were over 18 years of age and under 60 years of age and were diagnosed with insomnia based on Diagnostic and Statistical Manual (DSM‐IV) were included in the study. Patients were included when their body mass index was between 16.5 to 30 kg/m^2^. Another inclusion mandate was the ability of the patients to understand the sleep diary and their willingness to fill the sleep log dairy and follow other procedures required by the study protocol. Only those patients were considered who take more than 30 min to fall asleep and who reported subjective total sleep time of ≤ 6.5 hours per night. Moreover, habitual bedtime of between 8.30 pm and midnight was another inclusion criterion. Participants were excluded if they could not comply with the study protocol. The exclusion was also made if the subject had a history of seizures or significant head trauma, suffered from sleep disorder other than primary insomnia including restless leg syndrome and sleep apnea. Those who travelled across four or more time zones or worked on the night or rotating shifts in the previous seven days before study initiation were not considered. Subjects who had the plan to do work at night or follow a rotating shift during the study period and those who were taking any medications on a regular basis were excluded. Participants with clinically significant endocrine, metabolic, renal, hepatic, cardiovascular, gastrointestinal, respiratory, hematological or neurological illness and with any psychiatric disorders that can potentially result in insomnia were excluded. Individuals with substance abuse over a year, having alcohol and using tobacco were also considered ineligible.

Study procedures

In this 10-week long study, informed consent from each subject was obtained after screening and before enrolment. The participants were thoroughly screened for medical history, general physical conditions, and vital parameters. Once enrolled, the participants were assessed for the efficacy parameters for sleep assessments which include sleep actigraphy (Respironics Philips), PSQI, HAM-A scale, mental alertness on rising, sleep quality and sleep log \[[@REF23],[@REF24]\]. The safety parameters were assessed based on any adverse events reported.

The test product used in this study was KSM-66 Ashwagandha capsule, a proprietary root-only extract (300 mg) of Ashwagandha (Withania somnifera Dunal) and is manufactured by Ixoreal Biomed Inc., Los Angeles, California, USA. The product is light yellow in colour with the highest concentration of withanolides (5%\>). The placebo was a starch powder which was identical to test capsules. Both the test product and the placebo were coated in a capsule of exact shape, size, and colour. The batch number of the test product was KSM/14/270 which was manufactured in August 2014.

Capsules containing either Ashwagandha root extract (test) or placebo were used for intervention. Participants were instructed to take one capsule twice daily with milk or water for a period of 10 weeks. All the subjects were evaluated at the screening, baseline, 5th week and 10th week with the outcome measures. Physical examination and vital parameters of study participants were monitored during each visit. General examination and detailed monitoring of respiratory systems, cardiovascular systems, musculoskeletal system, digestive system and nervous system of each subject were done. In addition, measurements of systolic blood pressure, diastolic blood pressure, pulse rate, respiratory rate and body temperature of the subjects were noted in every visit.

Outcome measures of the study were the actigraphy parameters (sleep onset latency, total sleep time, wake after the onset of sleep), PSQI and HAM-A scores, mental alertness and sleep quality and total time in bed (TIB) (Figure [1](#FIG1){ref-type="fig"}).

Sleep actigraphy

Monitoring of rest and activity was performed using sleep actigraphy, a non-invasive, sensor-based procedure where the wearable part of the device can be placed on the wrist for the entire study duration to record movement. The procedure is validated against gold standard Nocturnal Polysomnogram.

SOL, TST, WASO and SE were the parameters assessed using the actigraphy. Clinically, the conversion period from full wakefulness to light sleep is termed as SOL. This stage often includes the initial stage of non-rapid eye movement sleep (NREMS). TST is referred to as the actual sleep time in a sleep period. Total sleep time is the cumulative outcome of the rapid eye movement sleep (REMS) and NREMS in an entire sleep period. WASO is the duration, a person remains awake after the defined onset of the sleep. Essentially, the estimation of WASO considers the specific wakefulness phase that is devoid of the duration prior to the sleep onset. SE refers to the actual time spent for sleep (total sleep) in comparison to the overall time spent in bed.

The computed data stored in the actigraphy devices were transferred to a computer for display and analysis of the period of wakefulness and sleep for all the subjects. Minimum three days continuous use of the actigraph was recommended for the enrolled patients to obtain a comprehensive view of the patient's sleep-wake pattern.

Total time in bed

Total time in bed was assessed by the individual sleep log, which was a daily, written record of the individual's sleep-wake pattern. The log contained information on the time of retiring and arising, time in bed, estimated total sleep period, number and duration of sleep interruptions, quality of sleep, daytime naps, use of medications or caffeine beverages per day and nature of waking activities.

Pittsburgh sleep quality index (PSQI)

The PSQI is a self-administered questionnaire resulting to a subjective measure of sleep quality and patterns through estimating the outcome of seven components of sleep quality, i.e., subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep-promoting medications, and daytime dysfunction over the period of a month \[[@REF23]\]. The summed up global score of the seven components estimates the patient's sleep quality that varies from 0 to 21. Higher the scores, worse the sleep quality.

Hamilton anxiety rating scale (HAM-A)

HAM-A is represented by 14 items \[[@REF24]\]. Every item individually encompasses a group of symptoms. This scale estimates both psychic anxiety and somatic anxiety including mental agitation and psychological distress; and physical complaints related to anxiety, respectively. Every item estimation score ranges between 0 and 4; higher the score, severe the situation. The total score ranges from 0 to 56. In this scale, score \<17 indicates mild severity, 18-24 represents mild to moderate severity, and 25-30 refers moderates to severe condition.

Mental alertness on rising

After waking up in the morning, the mental alertness was estimated through a three-point scale to assess the alertness as perceived by the patient where 1 refers to alert, 2 refers to slightly drowsy and 3 signifies extremely drowsy.

Sleep quality

Overall sleep quality was assessed using a seven-point scale as perceived by the patient after waking up in the morning. The scoring was considered as follows: 1 = Excellent, 2 = Very Good, 3 = Good, 4 = Fair, 5 = Poor, 6 = Very Poor and 7 = Extremely Poor.

Safety assessment

Clinical safety and tolerability were assessed based on the adverse events reported by the patients during the follow-up or during the clinical evaluation. Adverse events were recorded, along with their severity, duration and relationship to study drug.

Sample size and randomization

This was an exploratory study and it was planned to enroll 60 patients in the study. The sample size was not based on any statistical calculation or assumption. The enrolled 60 patients were randomized in a 2:1 ratio. Thus, 40 patients were considered in the experimental group (test product Ashwagandha capsules) and 20 patients were randomized to the control group (placebo group).

The randomization was done using PC-based software (Rando 1.2 R.Raveendran, 2004). The test and control products were packed in a way that the experimental and control study materials were identical in appearance. The packs were coded to conceal the nature of the drugs and the label contained the patient serial number which was the study ID. Once the participants were enrolled, they were provided with the study medication pack having the corresponding serial number. The randomization codes were provided in a separate sealed envelope for each participant and the envelope was opened by the investigator after the subjects were enrolled and received the serial number. Participants were not aware of their group assignments in this trial. Researchers and clinicians were blinded as well.

Statistical analysis

All the enrolled patients' data were collected as determined in the study protocol, i.e., during baseline estimation, at the 5th week and at the 10th week. Data were analyzed according to their randomized group, regardless of compliance with the treatment or any other deviation from protocol. All statistical analyses were done using windows based program Stata IC/13 (StataCorp LLC, USA). The analysis was conducted in both intent-to-treat (ITT) and per-protocol (PP) datasets. The obtained analysis outcome and scores are represented here as means with 1 standard deviation (SD) and 95% confidence intervals (CI). Baseline scores were compared to the post-treatment scores for the different scales using the Friedman test (repeat measures) within the group. The two groups were compared for differences using the one way analysis of variance (ANOVA). All testing was done using two-tailed tests at alpha 0.05.

Paired comparisons were done within each group for comparison of baseline scores with follow-up scores (five weeks and 10 weeks). Non-parametric tests for mental alertness and sleep quality were compared between data collections intervals using Kruskal-Wallis test and chi-square test.

Results
=======

A total of 85 participants were screened and assessed for eligibility initially, out of which, 25 participants failed eligibility criteria (Figure [2](#FIG2){ref-type="fig"}). The remaining 60 participants underwent randomization and were allocated to two groups: experimental and control group in a ratio of 2:1. Two participants (one from each group) withdrew from the study due to non-compliance to actigraphy (Figure [2](#FIG2){ref-type="fig"}). The analysis was continued using the data for the remaining 58 participants through per-protocol (PP) analysis. Table [7](#TAB7){ref-type="table"} (appendices) represents the study schedule followed.
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Demography

Demography of the patients is presented in Table [1](#TAB1){ref-type="table"}.

###### Demography of patients enrolled

BMI: Body mass Index

  ---------------------------------------- ------------- --------- --------------- ------- ------ --------------- ------- --------
                                           Ashwagandha   Placebo   ANOVA                                                  
                                           Mean          SD        95% C.I.        Mean    SD     95% C.I.        F       p
  Intent-to-treat (ITT) dataset (n = 60)                                                                                  
  N                                        40                                      20                                      
  Age (yrs.)                               38.83         5.00      37.23 - 40.42   40.00   6.21   37.09 - 42.90   0.626   0.432
  BMI (kg/sq.m)                            26.91         3.42      25.81 - 28.00   25.89   6.02   23.07 - 28.71   0.695   0.408
  Per-protocol (PP) dataset (n = 48)                                                                                      
  N                                        39                                      19                                      
  Age (yrs.)                               38.97         4.97      37.36 - 40.59   40.05   6.37   36.98 - 43.12   0.498   0.483
  BMI (kg/sq.m)                            26.87         3.46      25.75 - 28.00   25.28   5.50   22.62 - 27.93   1.834   0.181
                                                         No.       \%                      No.    \%                      p
  Gender (M/F)                                                                                                             
  ITT dataset                                            31/9      77.5%/22.5%             16/4   80.0%/20.0%             0.8261
  PP dataset                                             31/8      79.5%/20.5%             4      78.9%/21.1%             0.9263
  ---------------------------------------- ------------- --------- --------------- ------- ------ --------------- ------- --------

The two groups were similar with respect to the age, body mass index (BMI) and gender distribution at baseline.

Sleep parameters and actigraphy outcomes

Sleep parameters were recorded using an actigraphy watch on screening, baseline, week 5 and week 10 (Table [2](#TAB2){ref-type="table"}) and all the timings are expressed in minutes. At baseline, the mean (SD) SOL scores and mean WASO scores for the test group were 41.61 (6.84) and 42.69 (14.66), respectively. For the control group, the values were 41.94 (6.98) and 44.00 (12.43), correspondingly. After 10 weeks, the assessed scores for SOL and WASO were 29.00 (7.14) and 33.05 (14.36), respectively, recorded for the experimental group. For the control group, it was 33.94 (7.65) and 40.00 (12.26).

###### Sleep parameters with actigraphy in patients who completed study

  ------------------------------ ---------------------- ------------------ ---------------- ----------------- -------- ----------
                                 Ashwagandha (n = 39)   Placebo (n = 19)   ANOVA                                       
                                 Mean (SD)              95% C.I.           Mean (SD)        95% C.I.          F        Sig.
  Sleep onset latency (min)                                                                                             
  Baseline                       41.62 (6.84)           39.40 - 43.83      41.95 (6.99)     38.58 - 45.32     0.030    0.864
  5 weeks                        35.18 (7.04)           32.90 - 37.46      38.11 (7.01)     34.73 - 41.48     2.215    0.142
  10 weeks                       29.00 (7.15)           26.68 - 31.32      33.95 (7.66)     30.26 - 37.64     5.847    0.019
  Total sleep time (min)                                                                                                
  Baseline                       261.77 (34.78)         250.49 - 273.04    263.00 (42.72)   242.41 - 283.59   0.014    0.907
  5 weeks                        290.92 (35.61)         279.38 - 302.47    276.16 (43.46)   255.21 - 297.11   1.898    0.174
  10 weeks                       311.62 (35.81)         300.01 - 323.22    292.37 (42.47)   271.90 - 312.84   3.265    0.076
  Wake after sleep onset (min)                                                                                          
  Baseline                       42.69 (14.67)          37.94 - 47.45      44.00 (12.43)    38.01 - 49.99     0.112    0.740
  5 weeks                        38.21 (14.42)          33.53 - 42.88      41.84 (12.19)    35.96 - 47.72     0.895    0.348
  10 weeks                       33.05 (14.36)          28.40 - 37.71      40.00 (12.27)    34.09 - 45.91     3.276    0.076
  Total time in bed (min)                                                                                               
  Baseline                       346.08 (44.48)         331.66 - 360.50    348.95 (47.81)   325.90 - 371.99   0.051    0.823
  5 weeks                        364.31 (45.23)         349.65 - 378.97    356.11 (48.21)   332.87 - 379.34   0.403    0.528
  10 weeks                       373.67 (45.04)         359.07 - 388.27    366.32 (46.85)   343.74 - 388.90   0.332    0.567
  Sleep efficiency                                                                                                      
  Baseline                       75.63 (2.70)           74.76 - 76.51      75.14 (3.73)     73.34 - 76.94     0.322    0.573
  5 weeks                        79.91 (2.67)           79.04 - 80.77      77.35 (3.56)     75.64 - 79.07     9.356    0.003
  10 weeks                       83.49 (2.84)           82.57 - 84.41      79.68 (3.59)     77.95 - 81.41     19.265   \<0.0001
  ------------------------------ ---------------------- ------------------ ---------------- ----------------- -------- ----------

After completion of the study at 10th week, there was a significant decrease in SOL, WASO scores in the experimental group relative to the control group. The impact of the treatment is evident from the result.

In the case of total sleep time, the mean value at the baseline was 261.76 (34.78) for the experimental group and 263.00 (42.72) for the control group. At the end of the study, the scores recorded were 311.61 (35.80) for the experimental group and 292.36 (42.46) for the control group, respectively. In contrast to the SOL and WASO results, a significant increase was recorded in TST, TIB, and SE in the experimental group in comparison to the control group. The ANOVA results of the sleep parameters between the groups and within the groups are presented in Table [8](#TAB8){ref-type="table"} (appendices).

The outcome suggests that the mean total sleep time significantly increased for the experimental group after treatment. In continuation of the above observations, the mean change in the total time in bed (TIB) was noted higher in the experimental treatment group compared to the placebo (control) counterparts. At baseline, the total time in bed was 346.08 (44.48) for the experimental group and 348.94 (47.81) for control. At the end of the study (10th week), the obtained total time in bed was recorded as 373.66 (45.03) for the experimental group, and 366.31 (46.84) for the placebo or control group. Mean SE at baseline noted was 75.63 (2.70) for the experimental group and 75.14 (3.73) for the control group. The documented values at the end of the study were 83.48 (2.83) for the experimental group and 79.68 (3.58) for the control group, respectively. The difference in mean change between the two treatment groups was statistically significant (P \< 0.001).

A comparative analysis was conducted between the placebo and the test group to understand the participants' performance differences among various sleep parameters such as SOL, TST, TIB, and sleep efficiency as represented in Table [2](#TAB2){ref-type="table"}. The standard deviation values between the baseline measurements of the parameters and week 5 and week 10 suggest the significant differences along with the significant impact of the test product at the end of the study. Excellent improvement was observed for TST, TIB and overall sleep efficiency for the experimental group.

Figures [3](#FIG3){ref-type="fig"}-[7](#FIG7){ref-type="fig"} represent the trend observed throughout the study for the parameters considered, i.e., SOL, TST, WASO, TIB and SE, respectively.

![Sleep onset latency (minutes)](cureus-0011-00000005797-i03){#FIG3}

![Total sleep time (minutes)](cureus-0011-00000005797-i04){#FIG4}

![Wake after sleep onset (minutes)](cureus-0011-00000005797-i05){#FIG5}

![Total time in bed (minutes)](cureus-0011-00000005797-i06){#FIG6}

![Sleep efficiency (actigraphy)](cureus-0011-00000005797-i07){#FIG7}

PSQI outcomes

Greater PSQI score changes for the test group was documented at the end of the study compared to the baseline values. The mean PSQI score at the baseline was 13.07 (1.51) and 9.15 (1.82) at the end of the study for the test group. In comparison, the mean PSQI for the control group recorded at baseline was 13.47 (1.38), and at the end of the study, it was 11.8 (1.46). Table [3](#TAB3){ref-type="table"} and Figure [4](#FIG4){ref-type="fig"} demonstrate the PSQI scores of both the groups at baseline, week 5 and week 10. There was a significant decrease in the PSQI scores of the experimental group when compared to the control group. The gradual decrease in the PSQI scores is prominent in Figure [8](#FIG8){ref-type="fig"} for both the groups. The comparative measure further projects that the treatment with the Ashwagandha root extract powder depicted better outcome in comparison to the placebo group.

###### Sleep quality (PSQI) scores

  ---------- ---------------------- ------------------ -------------- --------------- -------- ----------
             Ashwagandha (n = 39)   Placebo (n = 19)   ANOVA                                   
             Mean (SD)              95% C.I.           Mean (SD)      95% C.I.        F        Sig.
  Baseline   13.08 (1.51)           12.59 - 13.57      13.47 (1.39)   12.80 - 14.14   0.927    0.340
  5 weeks    10.85 (1.71)           10.29 - 11.40      12.63 (1.50)   11.91 - 13.35   15.054   \<0.0001
  10 weeks   9.15 (1.83)            8.56 - 9.75        11.84 (1.46)   11.14 - 12.55   31.221   \<0.0001
  ---------- ---------------------- ------------------ -------------- --------------- -------- ----------
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Anxiety outcomes

The Hamilton Anxiety Rating Scale was used to determine anxiety. There was a significant decrease in the HAM-A score for the experimental group when compared with the control group. At baseline, the HAM-A scores were 23.58 (3.15) and 23.42 (3.00) for the experimental and control groups, respectively. At week 10, the HAM-A scores were 18.48 (3.47) and 21.52 (3.22), respectively. Table [4](#TAB4){ref-type="table"} and Figure [9](#FIG9){ref-type="fig"} demonstrate the HAM-A scores of both the groups at baseline, at week 5 and at week 10. Treatment with Ashwagandha resulted in comparative lower values than that of the placebo counterparts.

###### Anxiety (HAM-A) scores

  ---------- ---------------------- ------------------ -------------- --------------- -------- -------
             Ashwagandha (n = 39)   Placebo (n = 19)   ANOVA                                   
             Mean (SD)              95% C.I.           Mean (SD)      95% C.I.        F        Sig.
  Baseline   23.59 (3.15)           22.57 - 24.61      23.42 (3.01)   21.97 - 24.87   0.038    0.847
  5 weeks    20.69 (3.24)           19.64 - 21.74      22.37 (3.22)   20.82 - 23.92   3.437    0.069
  10 weeks   18.49 (3.48)           17.36 - 19.61      21.53 (3.22)   19.97 - 23.08   10.222   0.002
  ---------- ---------------------- ------------------ -------------- --------------- -------- -------
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Mental alertness on rising and sleep quality

Excellent sensory awareness with acceptable active attention is considered as mental awareness. Lower alertness is noted due to exhaustion, lack of energy, drowsiness, etc. whereas the alternative conditions may allow a person to be most active. The mental alertness on rising for the patients considered in this study was scaled as alert (score 1), slightly drowsy (score 2) and extremely drowsy (score 3). The data for mental alertness is presented in Table [5](#TAB5){ref-type="table"}.

###### Mental alertness on rising (% of pts.)

  ------------------ ---------------------- ------------------ ----------------------- ------- ------- -------
                     Ashwagandha (n = 39)   Placebo (n = 19)   Mann-Whitney 'U' test                   
                     No.                    \%                 No.                     \%      ^2^     p
  Baseline                                                                                              
  Alert              4                      10.3%              4                       21.1%   0.019   0.890
  Slightly Drowsy    23                     59.0%              8                       42.1%            
  Extremely Drowsy   12                     30.8%              7                       36.8%            
  5 weeks                                                                                               
  Alert              25                     64.1%              10                      52.6%   0.910   0.340
  Slightly Drowsy    11                     28.2%              6                       31.6%            
  Extremely Drowsy   3                      7.7%               3                       15.8%            
  10 weeks                                                                                              
  Alert              27                     69.2%              10                      52.6%   1.839   0.175
  Slightly Drowsy    11                     28.2%              7                       36.8%            
  Extremely Drowsy   1                      2.6%               2                       10.5%            
  ------------------ ---------------------- ------------------ ----------------------- ------- ------- -------

More number of patients with Ashwagandha were alert as compared to placebo at five weeks (p, 0.340) and 10 weeks (p, 0.175). A gradual improvement from the baseline to the final assessment in the tenth week was noted in both groups.

Sleep quality was assessed through the scale as mentioned in the method section. The statistical outcome of the non-parametric hypothesis testing on the per-protocol patients is presented in Table [6](#TAB6){ref-type="table"}. There is a gradual improvement in the sleep quality with Ashwagandha treated group whereas the placebo group does not show improvement. Better improvement with the test treatment versus placebo can be seen as the p-value has reduced over the study period (baseline, p = 0.697; five weeks, p = 0.281 and at 10 weeks, p = 0.002).

###### Sleep quality (% of pts.)

  ---------------- ---------------------- ------------------ ----------------------- ------- ------- -------
                   Ashwagandha (n = 39)   Placebo (n = 19)   Mann-Whitney 'U' test                   
                   No.                    \%                 No.                     \%      ^2^     p
  Baseline                                                                                            
  Fair             1                      2.6%               1                       5.3%    0.152   0.697
  Poor             16                     41.0%              6                       31.6%            
  Very Poor        15                     38.5%              8                       42.1%            
  Extremely Poor   7                      17.9%              4                       21.1%            
  5 weeks                                                                                             
  Very Good        1                      2.6%               0                       0.0%    1.162   0.281
  Good             8                      20.5%              1                       5.3%             
  Fair             10                     25.6%              6                       31.6%            
  Poor             13                     33.3%              8                       42.1%            
  Very Poor        6                      15.4%              4                       21.1%            
  Extremely Poor   1                      2.6%               0                       0.0%             
  10 weeks                                                                                            
  Excellent        1                      2.6%               0                       0.0%    9.481   0.002
  Very Good        8                      20.5%              0                       0.0%             
  Good             10                     25.6%              2                       10.5%            
  Fair             11                     28.2%              6                       31.6%            
  Poor             6                      15.4%              8                       42.1%            
  Very Poor        3                      7.7%               3                       15.8%            
  ---------------- ---------------------- ------------------ ----------------------- ------- ------- -------

Safety outcomes

None of the patients reported any adverse events during the study period.

Discussion
==========

Insomnia has become a global concern due to the modern urban lifestyle and other socio-economic changes. The recent global survey suggests that insomnia has become a common problem with complaints of associated stress, sleep apnea, hormonal imbalance as prime reasons. Often, chronic fatigue, endocrinological issues, energy depletion, lack of attention are the initial outcomes of chronic insomnia followed by illness associated with mild or severe disease conditions including blood pressure, depression, renal disease, cognitive impairment, diabetes, cardiovascular diseases, and others. Reduction of average sleep hours and increase in daily stress serves as the initial trigger for insomnia. Often, insomnia becomes clinically challenging to identify and characterize, an inspection of the clinical history can aid in understanding the factors contributing to the disease condition, behavioral treatment was also recommended by Buysse \[[@REF1]\].

The present treatment line pertaining to insomnia is discrete and multiple options have been attempted by the medical practitioners to counter the situation. The range of treatment varies from conventional medication such as neuropsychiatric drugs, cognitive behavioral therapy for insomnia (CBT-I), precision medicine, and alternative medicinal approaches. Earlier, a number of measures to negotiate chronic insomnia have been attempted including nonpharmacological treatment, bedtime restriction, use of receptor antagonists in relation to orexin system for sleep-onset insomnia \[[@REF25],[@REF26]\]. None of these strategies were found to provide an ultimate solution for the chronic or sleep onset insomnia conditions. Conventional sleep medications are associated with rebound insomnia and withdrawal whereas elderly patients often experience decline in cognition. Thus, alternative medicine may provide a reasonable solution in this regard. Different methods of using alternative medicine including personalized therapeutic trials applying the herbal products have been recommended \[[@REF27]\].

Among various alternative approaches attempted to tackle insomnia, herbal therapies have shown promises. A number of herbal sources have shown reasonable outcome including Ashwagandha. Application of Ashwagandha along with traditional Ayurvedic system also provided the desired result \[[@REF28]\]. Proven efficacy and safety of the use of Ashwagandha through clinical studies have been documented earlier including reproductive issues, stress and anxiety, cardiorespiratory endurance and in other ailments \[[@REF16],[@REF18],[@REF29]\].

The present study is the first report in the direction of clinical research where the scientific clinical study is conducted to understand the effect of Ashwagandha root extract on sleep quality in the considered patient population. Various sleep parameters were included in this study along with the level of anxiety in a 10-week treatment period, and the outcome was compared with a placebo via a randomized, double-blind, controlled clinical trial. Significant improvement of different components of sleep quality, sleep onset latency, and reduced anxiety was observed while using Ashwagandha root extract in participants for the insomnia patients compared to the placebo group. Kaushik et al. reported that the active ingredient of Ashwagandha leaves such as tryethylene glycol can induce sleep in mice through reducing the NREM sleep onset latency period \[[@REF30]\].

The present 10 weeks study reports the demonstrated impact of the significant improvement in the sleep parameters SOL, SE, PSQI and anxiety parameters HAM-A. The obtained differences with the placebo group were found statistically significant, suggesting a substantial effect of Ashwagandha in improving the sleep and reducing the anxiety of the subjects.

Limitations

The accommodated sample size of the study was large enough to extract statistical inference but was not enough to draw a general conclusion on the impact of the supplement used. A large randomized controlled study may yield further information related to the population-wide safety and efficacy of the herbal product. Furthermore, though the enrolled subjects had sleep issues, none had any psychological illness or any other systemic illness. Studies using a wider set of clinical backgrounds would be illuminating. Similarly, the study duration should be increased to understand the long-term effect of Ashwagandha in patients with insomnia and anxiety.

Conclusions
===========

Available conventional therapies of insomnia are known to develop drug dependency and exert side effects. Ashwagandha extract is a natural compound with sleep-inducing potential is well tolerated and improves sleep quality and sleep onset latency in patients with insomnia at a dose of 300 mg extract twice daily. It could be a potential candidate for treatment of insomnia and anxiety.
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###### Study schedule

  ----------------------------------------- ----------------- ---------------- ------------------ -------------------
  Visit                                     V1                V2               V3                 V4
  Day                                       Screening Day 3   Baseline Day 0   5 Weeks ± 2 Days   10 Weeks ± 2 Days
  Informed consent                          √                 X                X                  X
  Demographics and Medical history          √                 X                X                  X
  Screening and Enrolment                   √                 X                X                  X
  Physical examination & vital parameters   √                 √                √                  √
  Study Medication Dispensing               X                 √                X                  X
  Actiwatch (sleep actigraphy)              √                 √                √                  √
  Pittsburgh Sleep Quality Index (PSQI)     √                 √                √                  √
  Hamilton Anxiety Rating Scale (HAM-A)     √                 X                √                  √
  Mental alertness on rising                √                 X                √                  √
  Sleep quality                             √                 X                √                  √
  Sleep Log                                 X                 √                √                  √
  Medication Compliance                     X                 X                √                  √
  Adverse Events                            √                 √                √                  √
  Concomitant Illness                       √                 X                X                  X
  Concomitant medication                    √                 √                √                  √
  Study Completion/Termination              X                 X                X                  √
  ----------------------------------------- ----------------- ---------------- ------------------ -------------------

###### ANOVA table for sleep parameters in PP dataset (n = 58)

WASO: Wake after sleep onset; ANOVA: Analysis of variance; PP: Per-protocol.

  --------------------------------------- ---------------- ---------- ------------- ---------- -------- ----------
                                          Sum of Squares   df         Mean Square   F          Sig.     
  Sleep Onset Latency (min.) - Baseline   Between Groups   1.408      1             1.408      .030     0.864
  Within Groups                           2656.178         56         47.432                            
  Total                                   2657.586         57                                           
  Sleep Onset Latency (min.) - 5 weeks    Between Groups   109.363    1             109.363    2.215    0.142
  Within Groups                           2765.533         56         49.385                            
  Total                                   2874.897         57                                           
  Sleep Onset Latency (min.) - 10 weeks   Between Groups   312.708    1             312.708    5.847    0.019
  Within Groups                           2994.947         56         53.481                            
  Total                                   3307.655         57                                           
  Total Sleep Time(min.) - Baseline       Between Groups   19.353     1             19.353     .014     0.907
  Within Groups                           78826.923        56         1407.624                          
  Total                                   78846.276        57                                           
  Total Sleep Time (min.) - 5 weeks       Between Groups   2785.273   1             2785.273   1.898    0.174
  Within Groups                           82183.296        56         1467.559                          
  Total                                   84968.569        57                                           
  Total Sleep Time (min.) - 10 weeks      Between Groups   4732.762   1             4732.762   3.265    0.076
  Within Groups                           81179.652        56         1449.637                          
  Total                                   85912.414        57                                           
  WASO (min.) - Baseline                  Between Groups   21.847     1             21.847     .112     0.740
  Within Groups                           10958.308        56         195.684                           
  Total                                   10980.155        57                                           
  WASO (min.) - 5 weeks                   Between Groups   168.994    1             168.994    .895     0.348
  Within Groups                           10576.885        56         188.873                           
  Total                                   10745.879        57                                           
  WASO (min.) - 10 weeks                  Between Groups   616.878    1             616.878    3.276    0.076
  Within Groups                           10545.897        56         188.320                           
  Total                                   11162.776        57                                           
  Time in Bed (min.) - Baseline           Between Groups   105.266    1             105.266    .051     0.823
  Within Groups                           116343.717       56         2077.566                          
  Total                                   116448.983       57                                           
  Time in Bed (min.) - 5 weeks            Between Groups   859.558    1             859.558    .403     0.528
  Within Groups                           119558.097       56         2134.966                          
  Total                                   120417.655       57                                           
  Time in Bed (min.) - 10 weeks           Between Groups   690.349    1             690.349    .332     0.567
  Within Groups                           116588.772       56         2081.942                          
  Total                                   117279.121       57                                           
  Sleep Efficiency (SE) - Baseline        Between Groups   3.034      1             3.034      .322     0.573
  Within Groups                           527.412          56         9.418                             
  Total                                   530.446          57                                           
  Sleep Efficiency (SE) - 5 weeks         Between Groups   83.290     1             83.290     9.356    0.003
  Within Groups                           498.508          56         8.902                             
  Total                                   581.798          57                                           
  Sleep Efficiency (SE) - 10 weeks        Between Groups   184.805    1             184.805    19.265   \<0.0001
  Within Groups                           537.192          56         9.593                             
  Total                                   721.997          57                                           
  --------------------------------------- ---------------- ---------- ------------- ---------- -------- ----------
